Big Pharma Split (TSX:PRM) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:PRM Big Pharma Split Corp TSX:PRM
7 GF Score
Price C$11.61
GF Value C$1.80
View Full Analysis

What is Big Pharma Split 3-Month Share Buyback Ratio?

Big Pharma Split TSX:PRM 7 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates TSX:PRM with a GF Score™ of 7/100 and a GF Value™ of C$1.80.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

TSX:PRM
7GF Score
Big Pharma Split Corp TSX:PRM
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Big Pharma Split (TSX:PRM) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Big Pharma Split and its competitors.
Is Big Pharma Split's 3-Month Share Buyback Ratio too high?
Big Pharma Split's current 3-Month Share Buyback Ratio is 0.00. Overall, Big Pharma Split has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Big Pharma Split's 3-Month Share Buyback Ratio compare to BLK and BX?
Big Pharma Split's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for an Asset Management company?
A good 3-Month Share Buyback Ratio depends on the Asset Management industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Big Pharma Split and its competitors. Big Pharma Split's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Big Pharma Split stock overvalued right now?
Big Pharma Split (TSX:PRM) has a current 3-Month Share Buyback Ratio of 0.00. The stock's GF Value™ is C$1.80, compared to a current price of C$11.61 — trading 545% above its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Big Pharma Split's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Big Pharma Split (TSX:PRM), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Big Pharma Split (TSX:PRM) Overvalued in 2026?

Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued. The current stock price of C$11.61 is trading 545% above its estimated GF Value™ of C$1.80.

Key valuation signals for TSX:PRM:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: C$1.80 vs. price of C$11.61 (545% above fair value)
  • GF Score™: 7/100

No single metric tells the full story. See the TSX:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Big Pharma Split Business Description

Other Exchanges PRM.PR.A.PFD:Canada
Address 610 Chartwell Road, Suite 204, Oakville, ON, CAN, L6J 4A5
Big Pharma Split Corp is a closed end mutual fund corporation. The investment objective of the company is to provide shareholders with fixed cumulative preferential quarterly cash distributions and regular monthly cash distributions. The company has a presence in the United States, France, and the United Kingdom.
7GF Score

Get the complete analysis for TSX:PRM

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$11.61
Price
C$1.80
GF Value